Physician profile
Laura E Murray
NPI 1457657397
$10,492.85
in general payments reported to CMS, 2019-2025
68 companies · $1,955 in 2025
The $1,955 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,330 · 2022: $2,183 · 2023: $1,893 · 2024: $2,131 · 2025: $1,955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,979.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,142.73 | 2021-2025 | |
| Amgen INC. | $712.87 | 2021-2025 | Repatha, Otezla, Evenity |
| Janssen Pharmaceuticals, INC | $672.06 | 2021-2025 | Xarelto, Spravato |
| Lilly USA, LLC | $589.86 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $568.75 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $499.87 | 2021-2025 | Airsupra, Nexium, Breztri |
| Otsuka America Pharmaceutical, INC. | $471.51 | 2021-2025 | Rexulti, Abilify Maintena |
| Viiv Healthcare Company | $405.31 | 2022-2025 | Apretude |
| Boehringer Ingelheim Pharmaceuticals, INC. | $332.78 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $255.45 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $245.36 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Gilead Sciences, INC. | $217.51 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $208.05 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $207.43 | 2021-2025 | Xifaxan, Trulance |
| Biohaven Pharmaceuticals, INC. | $170.72 | 2021 |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $156.32 | 2021-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $154.97 | 2022 | |
| Merck Sharp & Dohme LLC | $148.57 | 2021-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Novartis Pharmaceuticals Corporation | $139.75 | 2022-2024 | |
| Inspire Medical Systems, INC. | $123.65 | 2022 | |
| Exact Sciences Corporation | $114.02 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Urgo Medical North America, LLC | $105.01 | 2024-2025 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Eisai INC. | $104.19 | 2021 | |
| Amneal Pharmaceuticals LLC | $102.49 | 2022-2025 | Unithroid |
| Esperion Therapeutics, INC. | $96.72 | 2021-2023 | Nexletol |
| Corium, LLC | $90.50 | 2022-2024 | Azstarys |
| Idorsia Pharmaceuticals US INC | $88.69 | 2023-2024 | Quviviq |
| Adlon Therapeutics L.P. | $79.17 | 2021 | |
| Boston Scientific Corporation | $67.65 | 2022 | |
| Mannkind Corporation | $66.97 | 2022 | |
| Medtronic, INC. | $65.67 | 2021-2025 | Minimed 780g |
| Optinose US, INC. | $60.98 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $60.36 | 2022-2024 | Strensiq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $56.35 | 2022-2023 | |
| Ironshore Pharmaceuticals INC. | $53.87 | 2021-2023 | Jornay Pm |
| Abbott Laboratories | $49.86 | 2021-2024 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $45.52 | 2025 | Gemtesa |
| Abiomed | $44.84 | 2025 | |
| Allergan, INC. | $43.52 | 2021-2022 | |
| Davol INC. | $38.12 | 2025 | Phasix Mesh |
| Integra Lifesciences Corporation | $37.17 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Paratek Pharmaceuticals, INC. | $36.32 | 2021-2024 | Nuzyra |
| Seqirus USA INC | $34.18 | 2022 | |
| Amarin Pharma, INC. | $33.13 | 2021 | |
| Dexcom, INC. | $32.14 | 2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $31.18 | 2021-2022 | |
| Kaleo, INC. | $30.85 | 2021-2022 | |
| Acera Surgical, INC. | $29.61 | 2024 | Restrata Wound Matrix |
| Lucid Diagnostics INC. | $28.14 | 2022-2024 | |
| Nestle Healthcare Nutrition INC. | $27.24 | 2022 | |
| Ethicon US, LLC | $23.73 | 2025 | Ethicon, Vistaseal |
| Sanofi Pasteur INC. | $23.23 | 2022 | |
| Electromed, INC. | $21.84 | 2025 | Smartvest |
| Impel Pharmaceuticals INC. | $21.61 | 2023 | Trudhesa |
| Vertical Pharmaceuticals, LLC | $19.76 | 2025 | Relexxii |
| Daiichi Sankyo INC. | $19.29 | 2021 | |
| Corcept Therapeutics | $17.69 | 2025 | Korlym |
| Noven Therapeutics, LLC | $17.57 | 2024 | Xelstrym |
| Axsome Therapeutics, INC. | $17.53 | 2023 | Sunosi |
| Genentech USA, INC. | $15.88 | 2022 | |
| Jazz Pharmaceuticals INC. | $15.78 | 2021 | |
| Shield Therapeutics INC | $15.51 | 2023 | Accrufer |
| Horizon Therapeutics Plc | $15.16 | 2022 | |
| Supernus Pharmaceuticals, INC. | $14.90 | 2023 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $14.36 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $14.21 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.65 | 2022 | |
| Bausch Health US, LLC | $13.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.